Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kimberly Kearns

Nurse Practitioner, Adult Health Hoffman Estates, IL Nurse Practitioner

NPI 1477706083 CMS profile 10906031

2359 Hassell Rd, Hoffman Estates, IL 60169

Open in the dashboard

General payments

$530,776

986 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Kearns of Hoffman Estates, IL is reported in the CMS Open Payments database as having received $530,776 across 986 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,615 13
2024 General $216,824 376
2023 General $143,886 267
2022 General $132,589 256
2021 General $30,862 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Kearns
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Kimberly Kearns were reported at $6,615. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Kimberly Kearns Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $30,862 $138 $43–$438 $132
2022 $132,589 $165 $54–$494 $149
2023 $143,886 $178 $61–$549 $160
2024 $216,824 $186 $62–$575 $164
2025 $6,615 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $193,261 280 payments
  2. Janssen Scientific Affairs, LLC $120,529 171 payments
  3. Lilly USA, LLC $60,602 144 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $58,785 126 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $56,580 143 payments
  6. Eli Lilly and Company $9,721 18 payments
  7. Phathom Pharmaceuticals, Inc. $8,315 22 payments
  8. Aimmune Therapeutics, Inc. $7,269 16 payments
  9. E.R. Squibb & Sons, L.L.C. $4,360 9 payments
  10. Ironwood Pharmaceuticals, Inc $3,000 2 payments
  11. Other $8,355 55 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $317,653 170 payments
  2. Travel and Lodging $92,986 321 payments
  3. Consulting Fee $57,475 60 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $36,400 22 payments
  5. Food and Beverage $22,027 404 payments
  6. Honoraria $4,000 2 payments
  7. Education $235 7 payments
Products named General payments · program years 2021–2025
  1. STELARA $308,526 435 payments
  2. TREMFYA $99,559 107 payments
  3. ENTYVIO $49,066 101 payments
  4. XIFAXAN $29,933 70 payments
  5. TRULANCE $28,474 86 payments
  6. OMVOH $27,888 48 payments
  7. ZENPEP $6,248 13 payments
  8. VOQUEZNA Gastroenterology $5,072 18 payments
  9. RELISTOR $4,821 13 payments
  10. VOQUEZNA Gastroenterology $3,221 3 payments
  11. Other $19,889 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

516

Median for Nurse Practitioner: 389

Drug cost

$47,532

Median for Nurse Practitioner: $21,885

Branded share of claims

35.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 13 $15,350
Trulance Plecanatide Brand 11 $11,349
Mesalamine Generic 16 $10,207
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 30 $1,940
Pantoprazole Sodium Generic 139 $1,411
Budesonide Dr Budesonide Brand 11 $1,287
Colestipol Hcl Generic 12 $1,130
Esomeprazole Magnesium Generic 23 $1,047
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 67 $1,011
Omeprazole Generic 89 $961

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$33,374

Medicare's payments for the services billed

Medicare patients

323

Average age 74

Services billed

719

188 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 32%
Diabetes 27%
Chronic kidney disease 21%
Depression 21%
Cancer 17%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$50,925 — —
STELARA
$48,723 — —
ENTYVIO
$42,200 — —
OMVOH
$27,888 — —
XIFAXAN
$13,684 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

986 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record